Clinical Trial Update: ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of ONYX-015 with cisplatin and fluorouracil for advanced head and neck cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Lip and Oral Cavity Cancer
• Oropharyngeal Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• FLUOROURACIL (Fluorouracil)
• ONYX-015

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lip and Oral Cavity Cancer, Head and Neck Cancer | Phase 1 | Status: WITHDRAWN